** Shares of Capricor Therapeutics CAPR.O rise ~12% to $15.30 premarket
** Co says the U.S. FDA has granted Priority Review to its drug to treat a heart condition associated with Duchenne muscular dystrophy (DMD)
** DMD cardiomyopathy is a heart muscle disease that can develop in individuals with the genetic condition causing progressive muscle weakness
** FDA is set to decide on the cell therapy, deramiocel, by August 31
** 'Priority review' status reduces the review timeline to six months from the time of filing, compared to a standard review timeline of 10 months
** Up to last close, stock nearly tripled in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.